ASX - By Stock
|
SPL |
Re:
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
|
|
1HMac
|
150 |
31K |
8 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
150
|
31K
|
8
|
|
ASX - By Stock
|
RHY |
Re:
Ann: Close of Rights Issue
|
|
1HMac
|
49 |
11K |
2 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
49
|
11K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
|
|
1HMac
|
73 |
18K |
1 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
73
|
18K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: New clinical data for DEP cabazitaxel in prostate cancer
|
|
1HMac
|
34 |
9.5K |
7 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
34
|
9.5K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
negating PCR testing
|
|
1HMac
|
36 |
10K |
7 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
36
|
10K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
negating PCR testing
|
|
1HMac
|
36 |
10K |
4 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
36
|
10K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
negating PCR testing
|
|
1HMac
|
36 |
10K |
3 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
36
|
10K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
negating PCR testing
|
|
1HMac
|
36 |
10K |
4 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
36
|
10K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
negating PCR testing
|
|
1HMac
|
36 |
10K |
28 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
36
|
10K
|
28
|
|
ASX - By Stock
|
IDT |
Re:
Ann: Trading Halt
|
|
1HMac
|
159 |
50K |
6 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
159
|
50K
|
6
|
|
ASX - By Stock
|
IDT |
Re:
Ann: Trading Halt
|
|
1HMac
|
159 |
50K |
3 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
159
|
50K
|
3
|
|
ASX - By Stock
|
IDT |
Re:
Ann: Trading Halt
|
|
1HMac
|
159 |
50K |
1 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
159
|
50K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs DEP Research Agreement with US Biopharma Co
|
|
1HMac
|
28 |
7.2K |
11 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
28
|
7.2K
|
11
|
|
ASX - By Stock
|
SPL |
Re:
Ann: AGM Chairman address and CEO presentation
|
|
1HMac
|
75 |
20K |
0 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
75
|
20K
|
0
|
|
ASX - By Stock
|
IDT |
Re:
IDT media thread
|
|
1HMac
|
759 |
221K |
5 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
759
|
221K
|
5
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical Announces Expanded Medicare Reimbursement
|
|
1HMac
|
4 |
2.3K |
2 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
4
|
2.3K
|
2
|
|
ASX - By Stock
|
IDT |
Re:
Aussie mRNA manufacturer 2b DECIDED this week
|
|
1HMac
|
30 |
7.7K |
5 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
30
|
7.7K
|
5
|
|
ASX - By Stock
|
AST |
Re:
Ann: AusNet enters into Scheme Deed with Brookfield
|
|
1HMac
|
4 |
1.8K |
1 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
4
|
1.8K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Cashflow and Activities Report
|
|
1HMac
|
42 |
11K |
9 |
30/10/21 |
30/10/21 |
ASX - By Stock
|
42
|
11K
|
9
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Cashflow and Activities Report
|
|
1HMac
|
42 |
11K |
7 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
42
|
11K
|
7
|
|
ASX - By Stock
|
IDT |
Re:
IDT media thread
|
|
1HMac
|
759 |
221K |
12 |
24/10/21 |
24/10/21 |
ASX - By Stock
|
759
|
221K
|
12
|
|
ASX - By Stock
|
IDT |
Re:
Ann: IDT Executes Manufacturing Agreement With Monash
|
|
1HMac
|
99 |
29K |
2 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
99
|
29K
|
2
|
|
ASX - By Stock
|
AST |
Re:
Ann: AusNet - indicative, non-binding and conditional proposal
|
|
1HMac
|
37 |
11K |
2 |
20/09/21 |
20/09/21 |
ASX - By Stock
|
37
|
11K
|
2
|
|
ASX - By Stock
|
IDT |
Re:
Novavax and IDT Partnership
|
|
1HMac
|
118 |
31K |
1 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
118
|
31K
|
1
|
|
ASX - By Stock
|
IDT |
Re:
Novavax and IDT Partnership
|
|
1HMac
|
118 |
31K |
3 |
06/09/21 |
06/09/21 |
ASX - By Stock
|
118
|
31K
|
3
|
|
ASX - By Stock
|
IDT |
Re:
IDT offers rival bid to make 100 millions MRNA vaccines
|
|
1HMac
|
211 |
59K |
3 |
25/08/21 |
25/08/21 |
ASX - By Stock
|
211
|
59K
|
3
|
|
ASX - By Stock
|
SKI |
Re:
Ann: SKI enters into Scheme Implementation Deed
|
|
1HMac
|
19 |
7.5K |
5 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
19
|
7.5K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
|
|
1HMac
|
76 |
21K |
1 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
76
|
21K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
|
|
1HMac
|
76 |
21K |
3 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
76
|
21K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE partners with Harlequins in the UK
|
|
1HMac
|
37 |
12K |
2 |
11/05/21 |
11/05/21 |
ASX - By Stock
|
37
|
12K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE antiviral nasal spray registered in Europe
|
|
1HMac
|
131 |
36K |
1 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
131
|
36K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs DEP ADC Research Agreement with MSD
|
|
1HMac
|
62 |
20K |
8 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
62
|
20K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs DEP ADC Research Agreement with MSD
|
|
1HMac
|
62 |
20K |
10 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
62
|
20K
|
10
|
|
ASX - By Stock
|
SPL |
Re:
Governments stockpiling
|
|
1HMac
|
6 |
2.1K |
3 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
6
|
2.1K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Governments stockpiling
|
|
1HMac
|
6 |
2.1K |
6 |
08/02/21 |
08/02/21 |
ASX - By Stock
|
6
|
2.1K
|
6
|
|
ASX - By Stock
|
AVH |
Re:
Lot of current market interest in AVH
|
|
1HMac
|
23 |
11K |
2 |
21/01/21 |
21/01/21 |
ASX - By Stock
|
23
|
11K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Remember DEP progressing
|
|
1HMac
|
3 |
1.6K |
2 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
3
|
1.6K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
|
|
1HMac
|
325 |
118K |
7 |
04/01/21 |
04/01/21 |
ASX - By Stock
|
325
|
118K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Ann: AGM Chairman address and CEO presentation
|
|
1HMac
|
100 |
32K |
7 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
100
|
32K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Ann: AGM Chairman address and CEO presentation
|
|
1HMac
|
100 |
32K |
8 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
100
|
32K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Ann: AGM Chairman address and CEO presentation
|
|
1HMac
|
100 |
32K |
3 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
100
|
32K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 shows potent antiviral activity in RSV
|
|
1HMac
|
79 |
19K |
2 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
79
|
19K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
SPL7013: A broad spectrum antiviral with massive future earning potential
|
|
1HMac
|
42 |
15K |
1 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
42
|
15K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma completes oversubscribed A$45M placement
|
|
1HMac
|
43 |
17K |
14 |
30/09/20 |
30/09/20 |
ASX - By Stock
|
43
|
17K
|
14
|
|
ASX - By Stock
|
SPL |
Re:
Problem is its not been used at all in Australia on covid-19 patients.
|
|
1HMac
|
19 |
5.9K |
18 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
19
|
5.9K
|
18
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 nasal spray for COVID19 development update
|
|
1HMac
|
152 |
58K |
7 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
152
|
58K
|
7
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
|
|
1HMac
|
130 |
45K |
8 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
130
|
45K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma awarded $1M MRFF funding for COVID-19 spray
|
|
1HMac
|
45 |
13K |
6 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
45
|
13K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
1HMac
|
206 |
65K |
5 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
1HMac
|
206 |
65K |
5 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
206
|
65K
|
5
|
|